Roche data highlights the strength of the ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for…
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of…
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its…
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the…
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also…
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023 TEL AVIV, Israel–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and…
Complete Response Letter Received for AVT02 Biologics License Application TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and…
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals,…
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn’s Disease AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib, 45…
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship,…
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications AbbVie (NYSE: ABBV) announced today the intent to voluntarily withdraw, in the U.S., accelerated…
CoolSculpting® Elite Announces First Ever CoolMonth LAUNCHES THE COOLEST PROMOTION WITH A BUY 4, GET 4 DEAL AT PARTICIPATING PROVIDERS TO SUPPORT YOUR BODY CONTOURING JOURNEY IRVINE, Calif., April 3, 2023 /PRNewswire/…